Summary We have previously show-n that epidermal growxth factor (EGF) 
We have previously shown that a brief exposure to EGF enhances the cvtotoxicity of cisplatin and causes a longlasting change in morpholog-in the absence of any mitogenic effect in two human ovarian carcinoma cell lines designated 2008 and COLO 316 (Chn'sten et al.. 1990 ). Exposure of human ovarian carcinoma cells to 10 nm EGF for 1 h and then concurrently to EGF and cisplatin for another hour increased the sensitivitv to cisplatin 2-to 4-fold. as quantitated by the ratio of the ICro values using a clonogenic assay. Exposure of 2008 cells to EGF and cisplatin concurrently for 1 h induced the same degree of sensitisation to cisplatin. Time course experiments showed that sensitivity to cisplatin was maximal 3 h after a 1 h exposure to 10 n-m EGF. and that the effect had largely disappeared bv 24 h. The EGF-induced increase in sensitivitv of 2008 cells to cisplatin was not dependent on new protein synthesis: pretreatment with cvcloheximide. at a concentration sufficient to inhibit protein synthesis by 90%. did not block the effect. Cisplatin sensitivity was found to be dependent on both the EGF concentration and the EGF receptor number in mouse fibroblasts expressing the human EGF receptor after transfection with a pBPV plasmid construct containing the human EGF receptor gene under control of the transferrin receptor 3'-inducible regulator. Although the degree of EGF-induced enhancement of sensitivity to cisplatin was only in the range of 2-to 4-fold. this represents a potentially clinically significant effect since patients with acquired cisplatin resistance have relatively low levels of resistance (Inoue et al.. 1985 : Wilson et al.. 1987 : Wolf et al.. 1987 ) that can be partially overcome by increasing cisplatin dose by 2-fold (Howell et al.. 1987 : Kaye et al.. 1992 .
We now show that EGF enhances the in vitro toxicity of EGF against cell lines representative of a broad range of clinically important cancers. and that. in addition to enhancing cisplatin toxicity. EGF also enhances the toxicity of a number of chnically important chemotherapeutic agents. (Cohen and Carpenter. 1975 : Carpenter. 1979 : Carpenter and Zendegui. 1986 ).
Cell Lines
The following cell lines w-ere obtained from the Amenrcan Type Culture Collection or directly from the depositor of the cell line: A549 non-small-cell lunz cancer (Lieber et al.. 1976) . NCI-H596 adenosquamous lung cancer (BanksSchlegel et al.. 1985) . UMC 31 small-cell lung cancer cells (Graziano et al.. 1991) . GLC4 small-cell lung cancer cells (Zijlstra et al.. 1987) . UMSCCIOb head and neck cancer cells (Krause et al.. 1981) . UMSCClOb Pt-6S cisplatin-resistant head and neck cancer cells (Nakata et al.. 1994) . 5637 bladder cancer cells (Fogh et al.. 1977) . MIA PaCa-2 pancreatic cancer cells (Yunis et al.. 1977) . Du 145 prostate cancer (Mickey. 1977: Connollv and Rose. 1989) . COLO 205 colon cancer (Semple et al.. 1978) . KB-3-1 cervix cancer (Akiyama et al.. 1985) . SiHa cervix cancer (Friedl et al. 1970) . A431 epidermoid carcinoma of the skin (Giard et al.. 1973) . T-289 melanoma cells (Taetle et al.. 1987 
Coloni-forming assa'i in soft agar
Cells were trypsinised and resuspended in complete medium. aliquoted at 2 ml containing 10 000 cells per ml. and exposed to cisplatin and rhEGF concurrently for 1 h. The drugcontaining medium was removed and cells were resuspended in 5 ml of complete medium containing 0.36°o low melting temperature agarose at 37°C. The cell suspension was mixed well and then aliquoted at I ml per dish in triplicate onto prepared 35 mm dishes containing a basement layer of solidified 10o agarose. The cell-containing laver was allowed to solidify at 4'C for 10 mmn. and the dishes were incubated at 37°C in humidified 0oo carbon dioxide. Colonies greater than 125Ljm were counted after 5 days.
Results
Effect of rhEGF on cisplatin toxicity The effect of rhEGF on cellular sensitivity to the cy-totoxic effect of cisplatin was determined for a -ariets of cell lines representative of clinically-important types of human malignancies. To determine the effect of rhEGF on cisplatin toxicit. cells were exposed to rhEGF and cisplatin concurrently for I h. The concentration of rhEGF was fixed at 10 nm. and the concentration of cisplatin was varied to generate a survival curve spanninz 2 logs of tumour cell kill. As an example. Figure I shows the effect of rhEGF on cisplatin toxicity KATOIII and MKN45 tumours. In addition to enhancing the toxicity of cisplatin, and despite the lack of effect on colony growth, rhEGF caused marked changes in the morphology of those cell lines that exhibited chemosensitisation. Interestingly, in those cell lines in which rhEGF failed to enhance cisplatin toxicity, rhEGF did not induce morphological changes. It is conceivable that the changes in morphology, including the formation of marked dendritic processes, were the result of an EGFinduced activation of a differentiation program (Christen et al., 1990) . Even though, in our cell lines, sensitisation to cisplatin by EGF was associated with morphological changes induced by EGF, these two events represent two distinct EGF moduation of dsplatin bcity R Krontng et al (Haley, 1990) . Specifically, EGF receptor overexpression has been documented in different types of squamous cell cancer, colon cancer and ovarian cancer (Haley, 1990) . Hence these types of cancer would be expected to exhibit more pronounced enhancement of cisplatin toxicity in response to EGF than normal tissues expressing lower levels of the EGF receptor. Such differential expression of EGF receptor numbers is an important basis for the potential selectivity of the rhEGF cisplatin combination.
In addition to enhancing the sensitivity of 2008 human ovarian carcinoma cells to cisplatin, EGF was also found to enhance the in vitro toxicity of several other clinically important chemotherapeutic agents against 2008 cells. These agents included drugs with different mechanisms of action, such as carboplatin, tetraplatin. melphalan, taxol and 5-fluorouracil (Table II) . Amagase et al. (1989) (Isonishi et al., 1992) , the bombesin receptor (Isonishi et al., 1992) , protein kinase A (Mann et al., 1991) and protein kinase C (Isonishi et al., 1990) . Thus the concept is evolving that signal transduction pathways can regulate some components of the cellular response to drug-induced damage that are critical to the cell's ability to survive the insult. Moreover, such cellular damage itself activates a variety of these same pathways as has been reported for UV-B radiation, gamma-radiation and alkylating agents (Holbrook and Fornace, 1991; Devary et al., 1992) .
Recent findings have helped to shift the focus of attention from the classical concept that drug sensitivity is determined primarily by factors such as drug and target concentration to the idea that post-receptor events can play a critical role in whether a cell survives or dies. We are beginning to understand that drug target interactions are not alone responsible for cell death (Dive and Hickman, 1991) . Rather, the drug-target interaction and its sequelae, which include signalling events activated by the drug-target interaction, may act as the trigger for both protective responses and pathways activating cell death (Dive and Hickman, 1991) . Clearly, we can modulate cellular sensitivity by activating multiple different kinds of signal transduction pathways. The data that exist for chemotherapeutic agents, UV-B radiation and gamma-radiation suggest that the effect may not be at the level of the interaction with the primary target, but on some event triggered by this interaction. DNA-damaging agents clearly cause the activation of a variety of signal transduction pathways, and it may be that it is primarily on these damageinduced responses, both protective and destructive, that the modulator pathways are working. Abbreviatioa rhEGF, recombinant human epidermal growth factor: cisplatin (DDP), cisdiamminedichloroplatinum (II); IC%. dose level resulting in 50% inhibition of cell survival.
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